Related Experiment Videos
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine
K U Schallreuter1, E Wenzel, F W Brassow
1Department of Dermatology, University of Hamburg, Federal Republic of Germany.
Abstract:
To date, dacarbazine (DTIC) has been the most effective drug in the treatment of advanced metastatic melanoma, achieving response rates of up to 28% (mean, 21%). Multidrug responses were generally no better than those obtained using monotherapy. A quite promising clinical trial was conducted using the new nitrosourea fotemustine. A total of 19 patients presenting with advanced malignant melanoma (clinical stage IV according to the 1987 UICC classification system) underwent treatment involving a more rapid infusion of the drug and a reduction in the rest period from 5 to 3 weeks. This monotherapy with fotemustine yielded two complete responses and seven partial responses; in addition, four patients showed no change and six cases progressed after the induction cycle (median duration of response to date, 7.6 months, including four cases that have not relapsed). Fotemustine was well tolerated by the patients, with the only mild side effects being thrombocytopenia, leukocytopenia and easily controlled nausea/vomiting. Preclinical studies performed previously indicated that fotemustine inhibits enzymes involved in the ribonucleotide reduction pathway (i.e. DNA synthesis), whereby responding patients (n = 3) appeared to favor the thioredoxin reductase/thioredoxin electron transfer to ribonucleotide reductase, whereas non-responders (n = 4) expressed the alternate glutathione reductase/glutaredoxin mechanism. The 47% response rate obtained in these studies vs the 24% reported previously for fotemustine may reflect variations in enzymes in the ribonucleotide reduction pathway in different patients. However, the efficacy of fotemustine against advanced melanoma warrants more extensive trials of this drug, especially since the quality of life of the patients during and after chemotherapy was not severely affected.
Insights
Fotemustine shows promise as a new treatment for advanced melanoma, offering a good response rate with manageable side effects. Further clinical trials are recommended for this effective chemotherapy option.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Dacarbazine (DTIC) is the current standard for advanced metastatic melanoma, with response rates around 21%.
- Newer chemotherapeutic agents are needed to improve treatment outcomes for advanced melanoma.
Purpose of the Study:
- To evaluate the efficacy and tolerability of the nitrosourea fotemustine as a monotherapy for advanced malignant melanoma.
- To explore potential biomarkers related to treatment response in melanoma patients.
Main Methods:
- A clinical trial involving 19 patients with advanced malignant melanoma (UICC stage IV) treated with fotemustine monotherapy.
- Modified treatment schedule: rapid infusion and reduced rest period (3 weeks).
- Analysis of patient response, duration of response, side effects, and correlation with ribonucleotide reduction pathway enzymes.
Main Results:
- Fotemustine monotherapy achieved a 47% response rate (2 complete, 7 partial responses) in advanced melanoma patients.
- Median duration of response was 7.6 months, with 4 patients not relapsing.
- Fotemustine was well-tolerated, with mild thrombocytopenia, leukocytopenia, and nausea/vomiting as primary side effects.
- Preliminary data suggests a link between thioredoxin reductase/thioredoxin pathway and treatment response.
Conclusions:
- Fotemustine demonstrates significant efficacy and a favorable safety profile in treating advanced malignant melanoma.
- The drug's efficacy may be influenced by individual variations in the ribonucleotide reduction pathway.
- Fotemustine warrants further extensive clinical investigation for advanced melanoma treatment.